JP2012520342A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520342A5
JP2012520342A5 JP2012500227A JP2012500227A JP2012520342A5 JP 2012520342 A5 JP2012520342 A5 JP 2012520342A5 JP 2012500227 A JP2012500227 A JP 2012500227A JP 2012500227 A JP2012500227 A JP 2012500227A JP 2012520342 A5 JP2012520342 A5 JP 2012520342A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
alkoxy
phenyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012500227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/053418 external-priority patent/WO2010106082A1/en
Publication of JP2012520342A publication Critical patent/JP2012520342A/ja
Publication of JP2012520342A5 publication Critical patent/JP2012520342A5/ja
Pending legal-status Critical Current

Links

JP2012500227A 2009-03-16 2010-03-16 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート Pending JP2012520342A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16064209P 2009-03-16 2009-03-16
US61/160,642 2009-03-16
US17795809P 2009-05-13 2009-05-13
US61/177,958 2009-05-13
US22762009P 2009-07-22 2009-07-22
US61/227,620 2009-07-22
PCT/EP2010/053418 WO2010106082A1 (en) 2009-03-16 2010-03-16 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders

Publications (2)

Publication Number Publication Date
JP2012520342A JP2012520342A (ja) 2012-09-06
JP2012520342A5 true JP2012520342A5 (https=) 2013-05-09

Family

ID=42111633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012500227A Pending JP2012520342A (ja) 2009-03-16 2010-03-16 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート

Country Status (8)

Country Link
US (2) US8575217B2 (https=)
EP (1) EP2408443A1 (https=)
JP (1) JP2012520342A (https=)
CN (1) CN102427809B (https=)
AU (1) AU2010224866C1 (https=)
BR (1) BRPI1013878A2 (https=)
CA (1) CA2755069A1 (https=)
WO (1) WO2010106082A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
EP2291084A4 (en) 2008-05-20 2012-04-25 Neurogesx Inc CARBONATE PRODRUGS AND METHOD FOR THEIR USE
US8466197B2 (en) * 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
EP2654777A4 (en) * 2010-12-21 2014-07-09 Nestec Sa METHOD AND COMPOSITIONS FOR ADMINISTERING THE BLOOD SUGAR IN ANIMALS
JP6150306B2 (ja) * 2011-09-16 2017-06-21 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダＧｅｎｍｅｄｉｃａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓｌ 代謝異常を治療するのに有用な抗炎症剤及び抗酸化剤の抱合体を含む医薬配合物
WO2013037984A1 (en) 2011-09-16 2013-03-21 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
US9024055B2 (en) * 2011-09-22 2015-05-05 Acorda Therapeutics, Inc. Acetaminophen conjugates, compositions and methods of use thereof
US9273061B2 (en) * 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2014011624A2 (en) * 2012-07-10 2014-01-16 Xpd Holdings Llc Stabilized multi-functional antioxidant compounds and methods of use
US20150209442A1 (en) * 2012-08-31 2015-07-30 The Board Of Regents Of The University Of Texas System Method to improve pharmacokinetics of drugs
US9029342B2 (en) 2012-09-17 2015-05-12 Board Of Regents Of The University Of Texas System Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof
EP2716574B1 (en) 2012-10-02 2015-12-16 Reemtsma Cigarettenfabriken GmbH Package for tobacco related articles and method of manufacturing the package
WO2015037659A1 (ja) 2013-09-13 2015-03-19 株式会社医薬分子設計研究所 水溶液製剤及びその製造方法
US9630937B2 (en) 2013-11-08 2017-04-25 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
ES2786306T3 (es) 2014-02-06 2020-10-09 Biocogent Llc Composiciones y métodos mejorados que comprenden resveratrol
WO2016040342A1 (en) * 2014-09-08 2016-03-17 Kansas State University Research Foundation Early lactation administration of non-steroidal anti-inflammatory drugs to increase whole-lactation milk yield
WO2017015013A1 (en) * 2015-07-17 2017-01-26 The Board Of Regents Of The University Of Oklahoma Licofelone derivatives and methods of use
KR101601685B1 (ko) * 2015-08-24 2016-03-09 여명바이오켐 주식회사 항산화 효과가 우수한 택시폴린 유도체 및 이를 함유하는 화장료 조성물
WO2018174839A1 (en) * 2017-03-18 2018-09-27 Nguyen Mark Quang Cysteine, n-acetylcysteine and penicillamine prodrugs, pharmaceutical compositions thereof, and methods of use
WO2018170765A1 (zh) * 2017-03-22 2018-09-27 深圳市博奥康生物科技有限公司 Imd16基因的rna干涉载体及其应用
KR102048982B1 (ko) * 2017-11-10 2019-11-26 원광대학교 산학협력단 이데베논 유도체 화합물 및 이를 포함하는 화장료 조성물

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1583602A (en) 1977-05-26 1981-01-28 Sterwin Ag N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives
IT1134458B (it) 1980-11-26 1986-08-13 Real Sas Di Alberto Reiner Derivato della n-acetil-cisteina ad attivita' terapeutica,procedimento per la sua preparazione e relative composizioni farmaceutiche
IT1194117B (it) 1981-11-20 1988-09-14 Isnardi Pietro & C Spa Derivati salicilici di n-acetilcisteina
IT1190987B (it) 1982-09-07 1988-02-24 Pharma Edmond Srl Tioesteri dell'acido acetilsalicilico,procedimento per la loro preparazione e composizioni farmaceutiche che li conttengono
IT1206515B (it) 1983-08-09 1989-04-27 Guidotti & C Spa Labor N-acetilcisteina ederivati 2',4's-carbossimetilcisteina ad-difluoro-4-idrossi-(1,1'-bifenil)attivita' antinfiammatoria, 3-carbossilici della mucolitica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
US5948769A (en) 1984-01-28 1999-09-07 Ismail; Roshdy Agent for treating heart diseases
ES8609231A1 (es) 1985-12-03 1986-09-01 Farmhispania Procedimiento de obtencion del n-acetil-3(2-(acetiloxi)ben- zoilmercapto)alanina
ES8800144A1 (es) 1986-05-09 1987-11-01 Lasa Lab Procedimiento de obtencion de un tioester de la n-acetilcisteina y de sus sales de interes terapeutico
EP0254032A3 (en) 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
IT1213301B (it) 1986-07-14 1989-12-20 Zambon Spa Composizioni per il trattamento del le sindromi da ischemia e riperfusione
IT1228537B (it) 1987-07-30 1991-06-20 Magis Farmaceutici Derivati della cisteina ad azione espettorante
US5610180A (en) 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
US8178516B2 (en) 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
DE4327462A1 (de) 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
RU2054936C1 (ru) 1994-04-07 1996-02-27 Елизарова Евгения Павловна Мембраностабилизирующее средство для лечения больных с инсулинзависимым и инсулиннезависимым сахарным диабетом
DE4444051A1 (de) 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
US5871769A (en) 1996-01-18 1999-02-16 Fleming & Company, Pharmaceuticals Methods and compositions for the prevention and treatment of diabetes mellitus
JP2002511837A (ja) 1996-09-10 2002-04-16 メデイノックス，インコーポレイテッド ポリジチオカルバメート含有マクロ分子と、治療及び診断用途へのその使用
US6896899B2 (en) 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
CZ96798A3 (cs) 1997-04-02 1998-10-14 Sankyo Company Limited Deriváty dithiolanu, jejich příprava a jejich terapeutické účinky
AUPO612397A0 (en) 1997-04-11 1997-05-08 University Of Queensland, The Novel diflunisal esters and related compounds
CN1275596C (zh) 1997-05-14 2006-09-20 阿特罗吉尼克斯公司 普罗布考单酯在制备用于治疗心血管疾病和炎性疾病的药物中的应用
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
US20020004515A1 (en) 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US6288234B1 (en) 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
WO2000007575A2 (en) 1998-07-31 2000-02-17 Mount Sinai Hospital Methods and compositions for increasing insulin sensitivity
US20020045580A1 (en) 1999-11-24 2002-04-18 Sacks Meir S. Compositions for raising uric acid levels and methods of using same
EP1113804A2 (en) 1998-09-17 2001-07-11 Akesis Pharmaceuticals, Inc. Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
US6201028B1 (en) 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US20010051184A1 (en) 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
AU768189B2 (en) 1999-06-15 2003-12-04 Nutri-Logics, Inc. Nutrient formulations for disease reduction, and related treatment and component screening methods
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2001025226A1 (en) 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20020155163A1 (en) 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
US20080213785A1 (en) 2000-04-20 2008-09-04 Andrew Levy Method of predicting a benefit of antioxidant therapy for prevention or treatment of vasclar disease in hyperglycemic individuals
US20080044399A1 (en) 2000-04-20 2008-02-21 Andrew Levy Vitamin E supplementation for reducing cardiovascular events in individuals with DM and the Hp 2-2 genotype
US20020037855A1 (en) 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6365176B1 (en) 2000-08-08 2002-04-02 Functional Foods, Inc. Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy
IT1319201B1 (it) 2000-10-12 2003-09-26 Nicox Sa Farmaci per il diabete.
US20020098247A1 (en) 2000-11-02 2002-07-25 Komorowski James R. Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid
US6589948B1 (en) 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
ES2375268T3 (es) 2000-12-14 2012-02-28 The Brigham And Women's Hospital, Inc. Marcadores inflamatorios para la detección y prevención de diabetes mellitus.
EP1219304B1 (de) 2000-12-28 2004-10-20 Fresenius Kabi Austria GmbH Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
WO2004096256A1 (en) 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
JP2002226457A (ja) 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
JP4880190B2 (ja) 2001-04-30 2012-02-22 トロムスドルフ ゲーエムベーハー ウント コンパニー カーゲー アルツナイミッテル 医薬として活性なウリジンエステル
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2003024426A1 (en) 2001-09-21 2003-03-27 Egalet A/S Controlled release solid dispersions
FR2835433B1 (fr) 2002-02-01 2006-02-17 Richard Lab M Utilisation de la 1-(-4-chlorobenzoyl)-5methoxy-2-methyl-1h- indole-3acetic 4-(acetylamino)phenylester pour la fabrication d'un medicament destine a inhiber exclusivement la cox2
BR0308415A (pt) * 2002-03-14 2005-02-15 Bayer Pharmaceuticals Corp Métodos de tratamento de diabetes usando-se inibidores de pde11a
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US6960683B2 (en) 2002-07-12 2005-11-01 Atherogenics, Inc. Salt forms of poorly soluble probucol esters and ethers
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
CA2504329C (en) 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Geodate delivery vehicles
US8093292B2 (en) 2002-11-22 2012-01-10 Bionexus, Ltd. Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
CN1233629C (zh) 2002-11-22 2005-12-28 贵州省中国科学院天然产物化学重点实验室 具有神经营养作用的硫酯类化合物及其它的合成方法和应用
MXPA02012315A (es) 2002-12-13 2004-06-24 Univ Autonoma Metropolitana Compuesto farmaceutico que contiene silimarina y carbopol, su proceso de fabricacion y su uso como regenerador del tejido y celulas pancreaticas de secrecion endogena danados por diabetes mellitus.
US20090036516A1 (en) 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
US20050020654A1 (en) 2003-03-15 2005-01-27 Pershadsingh Harrihar A. Novel PPAR agonists, pharmaceutical compositions and uses thereof
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
AT500404A1 (de) 2003-07-17 2005-12-15 Jsw Res Forschungslabor Gmbh Chemische verbindungen enthaltend tocopherol sowie zumindest einen weiteren pharmazeutischen wirkstoff
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US20070041925A1 (en) 2003-09-22 2007-02-22 Beiersdorf Ag Skin and hair care preparation containing a combination of protein hydrolyzates
US20070254055A1 (en) 2003-11-21 2007-11-01 Trustees Of Tufts College Therapeutic Avenanthramide Compounds
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
US20050143356A1 (en) 2003-12-08 2005-06-30 Vanderbilt University Selective inhibition of cyclooxygenase 1 in the treatment of diabetic nephropathy
US20050171027A1 (en) 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
AU2004317520B2 (en) 2004-03-10 2011-06-09 Shimoda Biotech (Pty) Ltd Stable injectable diclofenac compositions
EP2266586A1 (en) 2004-03-23 2010-12-29 Lifeline Nutraceuticals Corporation Compositions and method for alleviating inflammation and oxidative stress in a mammal
WO2005112914A2 (en) 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
BRPI0511272A (pt) 2004-05-17 2007-12-04 Combinatorx Inc métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
JP4218601B2 (ja) 2004-06-29 2009-02-04 トヨタ自動車株式会社 圧縮着火内燃機関の空燃比センサ劣化判定システム
JP2008505176A (ja) * 2004-06-30 2008-02-21 コンビナトアールエックス インコーポレーティッド 代謝障害を治療するための方法および試薬
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JPWO2006043671A1 (ja) 2004-10-22 2008-05-22 キリンホールディングス株式会社 転写因子Ｎｒｆ２活性化剤およびその機能が付与された食品
US20060099279A1 (en) 2004-11-09 2006-05-11 Council Of Scientific & Industrial Research Novel anti-diabetic herbal formulation
CA2584845C (en) 2004-12-08 2009-02-17 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
EP1836160A1 (en) 2004-12-24 2007-09-26 CTG Pharma S.r.l. Compounds for treating metabolic syndrome
US20060166901A1 (en) 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
JP2008528510A (ja) 2005-01-20 2008-07-31 サートリス ファーマシューティカルズ， インコーポレイテッド 紅潮および／または薬物誘発性体重増加を処置するためのサーチュイン活性化化合物の使用
EP1845971A4 (en) * 2005-01-21 2009-12-30 Medvet Science Pty Ltd METHOD FOR THE TREATMENT OF CELL DAMAGE
US20060172012A1 (en) 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
US20080033027A1 (en) 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
WO2006102476A2 (en) 2005-03-21 2006-09-28 Vicus Therapeutics Spe 1, Llc Compositions and methods for ameliorating cachexia
US20090234011A1 (en) 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20090325975A1 (en) 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
EP1960356A2 (en) 2005-11-03 2008-08-27 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
DE102005057178A1 (de) 2005-11-30 2007-07-19 Basf Ag Verwendung von Zinksalzen der Liponsäure zur Behandlung von Fettstoffwechselstörungen
AU2006339607A1 (en) 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulators of Cdc2-like kinases (Clks) and methods of use thereof
WO2007067570A1 (en) 2005-12-05 2007-06-14 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
US20070231273A1 (en) 2006-03-31 2007-10-04 Jie Wu Method for Decreasing Blood Glucose Levels
WO2007117048A1 (en) 2006-04-10 2007-10-18 Seoul National University Industry Foundation Inhibitors against g6pd enzyme for treating and preventing oxidative stress and/or inflammatory related diseases and method for screening the same
US20080015251A1 (en) 2006-04-10 2008-01-17 Yissum Research Development Co., Of The Hebrew University Of Jerusalem Means and method for treating lipotoxicity and other metabolically related phenomena
EP2015742B1 (en) * 2006-04-28 2013-06-12 Joslin Diabetes Center, Inc. Reducing risk of type 2 diabetes (t2d)
WO2008010025A1 (en) * 2006-07-18 2008-01-24 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate
CA2656858C (en) * 2006-07-09 2016-01-19 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetylsalicylic acid
JP5542436B2 (ja) * 2006-07-25 2014-07-09 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚透過率を有するジクロフェナクの正荷電水溶性プロドラッグ
CN101500983B (zh) 2006-07-26 2015-09-16 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药
US20080139525A1 (en) 2006-08-31 2008-06-12 The Brigham And Women's Hospital, Inc. Antioxidant therapies
ES2670407T3 (es) * 2006-09-03 2018-05-30 Techfields Biochem Co. Ltd Profármacos de acetaminofén solubles en agua cargados positivamente y compuestos relacionados con una tasa de penetración de la piel muy rápida
WO2008127355A2 (en) 2006-10-06 2008-10-23 Celtaxsys, Inc. Chemorepulsion of cells
US7498048B2 (en) 2006-11-16 2009-03-03 Jose Angel Olalde Rangel Renal phyto-nutraceutical composition
ES2660173T3 (es) 2007-01-16 2018-03-21 Ipintl, Llc Nueva composición para el tratamiento del síndrome metabólico
JP2010520878A (ja) * 2007-03-08 2010-06-17 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性の調節剤としての化合物および組成物
US20090169497A1 (en) 2007-12-31 2009-07-02 Horwitz Lawrence D Treatment and Prevention of Skin Injury Due to Exposure to Ultraviolet Light
WO2009089011A2 (en) 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
CN102316730A (zh) * 2008-05-09 2012-01-11 天雅瑞药业有限公司 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
CA2724023C (en) 2008-05-13 2014-02-18 Genmedica Therapeutics Sl Salicylate conjugates useful for treating metabolic disorders
US20100239552A1 (en) 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination Therapies for Treating Metabolic Disorders

Similar Documents

Publication Publication Date Title
JP2012520342A5 (https=)
RU2006105717A (ru) Производные пиперазина и их применение в качестве терапевтических агентов
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
NZ601126A (en) Voltage-gated sodium channel blockers
SE0401971D0 (sv) Piperidne derivatives
WO2008148868A8 (en) Piperidine/piperazine derivatives
NZ601408A (en) Novel 3-hydroxy-5-arylisothiazole derivative
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
NZ598294A (en) Heterocyclic compounds for the inhibition of pask
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
UA105671C2 (uk) Фармацевтична композиція, яка містить похідне хіноліну
MX2009011867A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
RU2010139285A (ru) Производные пиридазина и их применение в качестве терапевтических агентов для лечения кожных нарушений
NZ601121A (en) 5-alkynyl-pyrimidines
JP2011505347A5 (https=)
PE20100083A1 (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
SI2228064T1 (sl) Farmacevtski sestavek, ki vsebuje glikopirolat in agonist adrenoceptorja beta2
MXPA05008600A (es) Compuestos para el tratamiento de desordenes metabolicos.
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
WO2009134616A3 (en) Novel inhibitors of hepatitis c virus replication
SE9904413D0 (sv) Comminuted form
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
NZ591814A (en) Pesticidal composition comprising an alpha-alkoxyphenyl acetic acid derivative and a neonicotinoid compound
WO2008088039A1 (ja) ドネペジルを含有する安定化医薬組成物、その製造方法、及び安定化方法